[{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ceftazidime","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alkem Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkem Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aztreonam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aztreonam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Avibactam

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Emblaveo (aztreonam-avibactam), a beta-lactamase inhibitor, is FDA approved for treating adult patients with complicated intra-abdominal infections, HAP, and cUTIs, including pyelonephritis.

                          Brand Name : Emblaveo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 22, 2024

                          Lead Product(s) : Aztreonam,Avibactam,Metronidazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ATM-AVI (aztreonam-avibactam) is an investigational treatment for infections caused by Gram-negative bacteria with limited treatment options. It combines aztreonam, a monobactam β-lactam, with avibactam, a recent broad-spectrum β-lactamase inhibitor.

                          Brand Name : ATM-AVI

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 01, 2023

                          Lead Product(s) : Aztreonam,Avibactam,Metronidazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Zidavi, which is a novel combination of ceftazidime and avibactam, a preferred treatment against OXA-48-like and Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae for pyelonephritis or Complicated Urinary Tract Infecti...

                          Brand Name : Zidavi

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 31, 2023

                          Lead Product(s) : Ceftazidime,Avibactam

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank